CSV November 24, 2022 through November 24, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POWDERED	COMPOSITION	*USP39–NF34*	6868	27-Jan-2017	1-Feb-2017	*USP41–NF36*	*Second*	Line 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TURMERIC EXTRACT	*/Content of C urc uminoi ds/ Chromatographi c system*						*Supplement to USP40–NF35*	*Column*: Change 4.6-mm × 20-cm; to: 4.6-mm × 25-cm;
PROMETHAZINE HYDROCHLORIDE ORAL SOLUTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Second Supplement to USP39–NF34*	8787	27-Jan-2017	1-Feb-2017	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 2 of USP Promethazine Related Compound B RS: Change Isopromethazine; *N*,*N* -
								H -phenothiazin-10-yl)propan-1-amine. $C_{17}H_{20}N_2S$ 282.42 to: Isopromethazine hydrochloride; *N*,*N* -

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								H-phenothiazin-10-yl)propan-1-amine hydrochloride. $C_{17}H_{20}N_2S \cdot HCl$ 320.88
THEOPHYLLINE ORAL SOLUTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Second Supplement to USP39–NF34*	8846	27-Jan-2017	1-Feb-2017	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 3 of USP Theophylline Related Compound D RS: Change *N*-Methyl-5-(methylamino)-1*H*-imidazole-4-carboxamide. $C_6H_{10}N_4O$ 154.17 to: *N*-Methyl-5-(methylamino)-1*H*-imidazole-4-carboxamide hydrochloride monohydrate.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ATROPINE SULFATE	DEFINITION	*USP39–NF34*	2638	27-Jan-2017	1-Feb-2017	*USP41–NF36*	*Second Supplement to USP40–NF35*	$C_6H_{10}N_4O \cdot HCl \cdot H_2O$ 208.65 Line 2: Change $(C_{17}H_{23}NO_{32} \cdot H_2SO_4)$, to: $[(C_{17}H_{23}NO_3)_2 \cdot H_2SO_4]$,
GALANTAMINE EXTENDED-RELEASE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>/Test 3*	*USP40–NF35*	4367	27-Jan-2017	1-Feb-2017	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 1of *Buffer*: Change To each L of 6.8-g/L potassium phosphate to: To each L of 6.8 g/L of monobasic potassium phosphate
AUXILIARY PACKAGING COMPONENTS	*Silica Gel/Inorganic Impurities*	*USP39–NF34*	510	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 1 of *Soluble ionizable salts*: Change (as $NaSO_3$): to: (as Na_2SO_4):
DIGOXIN INJECTION	IDENTIFICATION/*B.*	*USP39–NF34*	3493	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 1 of *Procedure*: Change Proceed as

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								directed for *Procedure* in the test for *Related glycosides* under *Digoxin*, except to omit the use of the *Gitoxin standard solution*. to: Apply 10 µL of the *Test solution* and 10 µL of the *Standard solution* on a line parallel to and about 2.5 cm from the bottom edge of a reversed-phase thin-layer chromatographic plate coated with a 0.25-mm layer of chromatographic silica gel mixture to which is

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								permanently bonded octadecylsilane (C18). Allow the spots to dry, and place the plates in a developing chamber containing a mixture of methanol and water (7:3). Develop the chromatogram until the solvent front has moved about 15 cm above the line of application. Remove the plate, and allow the solvent to evaporate. Spray the plate with *Chloramine T–trichloroacetic acid reagent*, freshly mixed, and heat in an oven at 110°

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POWDERED CHASTE TREE EXTRACT	CONTAMINANTS	*USP39–NF34*	6553	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	for 10 minutes. Change *Microbial Enumeration Tests <2021>*: The total bacterial count does not exceed 10^4 cfu/g. The total combined molds and yeasts count does not exceed 1000 cfu/g. It meets the requirements of the tests for absence of *Salmonella* species and *Escherichia coli*. to: *Microbial Enumeration Tests <2021>*: The total bacterial count does not exceed 10^4

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								cfu/g. The total combined molds and yeasts count does not exceed 10^3 cfu/g. *Absence of Specified Microorganisms <2022>*: Meets the requirements of the tests for absence of *Salmonella* species and *Escherichia coli*
NAPHAZOLINE HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*First Supplement to USP39–NF34*	8105	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 16 of *Analysis*: Change Calculate the percentage of any individual unspecified impurity to: Calculate the percentage of any other individual

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								impurity AND Line 20 of *Analysis*: Change r_U = peak response of any individual unspecified impurity to: r_U = peak response of any other individual impurity
OMEGA-3-ACID ETHYL ESTERS CAPSULES	SPECIFIC TESTS/ *Concentration of Omega-3-Acid Ethyl Esters*	*Second Supplement to USP39–NF34*	8755	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 21: Change C_U = nominal concentration of the total omega-3-acid ethyl esters in the *Sample solution* (g/mL) to: C_U = Capsule fill content of the *Sample solution* (g/mL)
CYCLOBENZAPRINE HYDRO	ADDITIONAL REQUIREMENT	*USP39–NF34*	3333	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to*	Line 2 of USP Cyclobenzaprine

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CHLORIDE	S/*USP Reference Standards <11>*						*USP40–NF35*	Related Compound B RS: Change 3-(5*H*-Dibenzo[*a,d*]cyclohepten-5-ylidene)-*N*-methyl-1-propanamine. $C_{19}H_{19}N$ 261.36 to: 3-(5*H*-Dibenzo[*a,d*]cyclohepten-5-ylidene)-*N*-methyl-1-propanamine hydrochloride. $C_{19}H_{19}N \cdot HCl$ 297.82
RIBOFLAVIN 5?-PHOSPHATE SODIUM	ASSAY/*Procedure*	*USP39–NF34*	5698	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 2 of *Instrumental conditions*: Change *Nephelometry, Turbidimetry, and Visual*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Comparison <855> to: *Fluorescence Spectroscopy* <853>
GUAR GUM	ASSAY/*Content of Galactomannan and Ratio of Constituting Mannose and Galactose*	*First Supplement to USP39–NF34*	7964	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 4 of *Analysis*: Change *Standard solution B* to: *Sample solution B*
DEXTROSE	IDENTIFICATION/*C. Water Determination <921>*	*Second Supplement to USP39–NF34*	8612	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 1: Change *Water Determination <921>* to: *Water Determination <921>, Method I*
PLASTIC MATERIALS OF CONSTRUCTION	TEST METHODS	*USP40–NF35*	542	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 1 of *Physicochemical Tests/Acidity or Alkalinity/BRP indicator solution*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								1.0 mg/mL of bromophenol blue, to: 1.0 mg/mL of bromothymol blue, AND Line 3 of *Plastic Additives/ Polyethylene, Cyclic Olefins, and Polypropylene/Phenolic Antioxidants/Test B*: Change tris(2, 4-di-*tert*-butylphenyl) phosphate; to: tris(2, 4-di-*tert*-butylphenyl) phosphite; AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Line 1 of *Plastic Additives/Polyethylene, Cyclic Olefins, and Polypropylene/Phenolic Antioxidants/Test C/Mobile phase*: Change (55:45:5, v/v/v) to: (50:45:5, v/v/v) AND Line 1 of *Plastic Additives/Polyethylene, Cyclic Olefins, and Polypropylene/Nonphenolic Antioxidant*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								s/ Chromatographic system/ Application: Change 20 µL of *Sample solution S10,* reference solution (*o*) and the reference solutions corresponding to to: 20 µL of *Sample solution S10* and the reference solutions corresponding to AND Line 2 of *Plastic Additives/Plasticized Polyvinyl Chloride/USP Reference Standards <11>/USP*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Plastic Additive 05 RS: Change Tris(2,4-di-*tert* -butylphenyl) phosphate. to: Tris(2,4-di-*tert* -butylphenyl) phosphite.
BETAXOLOL OPHTHALMIC SOLUTION	IM PUR ITIES/*Organic Impurities*	*USP39–NF34*	2749	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 14 of *Analysis*: Change M_{r1} = molecular weight of betaxolol hydrochloride, 343.89 M_{r2} = molecular weight of betaxolol, 307.43 to: M_{r1} = molecular weight of betaxolol, 307.43 M_{r2} = molecular weight of betaxolol

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hydrochloride, 343.89
DIGOXIN ORAL SOLUTION	IDENTIFICATION/*B.*	*USP39–NF34*	3493	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the test for *Related glycosides* under *Digoxin*, except to omit the use of the *Gitoxin standard solution*. to: Apply 10 µL of the *Test solution* and 10 µL of the *Standard solution* on a line parallel to and about 2.5 cm from the bottom edge of a reversed-phase thin-layer chromatographi

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								c plate coated with a 0.25-mm layer of chromatographic silica gel mixture to which is permanently bonded octadecylsilane (C18). Allow the spots to dry, and place the plates in a developing chamber containing a mixture of methanol and water (7:3). Develop the chromatogram until the solvent front has moved about 15 cm above the line of application. Remove the plate, and allow the solvent to evaporate. Spray the plate

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								with *Chloramine T–trichloroacetic acid reagent*, freshly mixed, and heat in an oven at 110° for 10 minutes.
CHONDROITIN SULFATE SODIUM	IMPURITIES	*USP39–NF34*	6566	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 1 of *Residue on Ignition <281>*: Change 20.0%–30.0% to: 20.0%–30.0% on the dried basis
CIPROFLOXACIN	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Second Supplement to USP39–NF34*	8597	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 2 of USP Ciprofloxacin Ethylenediamine Analog RS: Change 7-(2-Aminoethylamino)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid. $C_{15}H_{16}FN_3O_3$ 305.30 to: 1-Cyclopropyl-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								6-fluoro-1,4-dihydro-4-oxo-7-[(2-aminoethyl)amino]-3-quinolinecarboxylic acid hydrochloride. $C_{15}H_{16}FN_3O_3 \cdot HCl$ 341.77
POVIDONE	IMPURITIES/*Formic Acid*	*Second Supplement to USP39–NF34*	8778	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 3 of *Sample solution*: Change column of about 80 mm to: column of about 8 mm
PLASTIC PACKAGING SYSTEMS FOR PHARMACEUTICAL USE	TEST METHODS/*Physicochemical Tests/Water Extraction/Acidity or alkalinity*	*USP39–NF34*	506	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 2 of *Methyl red TS 2*: Change NMT 0.1 mL of 0.02 N hydrochloric acid to: NMT 0.1 mL of 0.02 N sodium hydroxide
DESMOPRESSIN ACETATE	IDENTIFICATION/*A. Mass Spectral*	*USP39–NF34*	3387	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 6 of *Instrumental conditions*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Analysis							Delete *Flow rate*: 0.7 mL/min *Injection volume*: 10 µL/min
SUCCINYLCHOLINE CHLORIDE INJECTION	IDENTIFICATION	*USP39–NF34*	5922	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 1: Change It responds to *Identification* tests *B* and *C* under *Succinylcholine Chloride*. to: *A*. The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*. *B*. *Thin-Layer Chromatographic Identification Test* <201> *Standard solution*: 1

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mg/mL of USP Succinylcholine Chloride RS in water *Sample solution*: Nominally 1 mg/mL of succinylcholine chloride from Injection in water *Chromatographic system* (See *Chromatography* <621>, *Thin-Layer Chromatography*.) *Adsorbent*: 0.25-mm layer of chromatographic silica gel *Application volume*: 1 µL *Developing solvent system*: Acetone and 1 N hydrochloric acid (1:1) *Analysis*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Samples: *Standard solution* and *Sample solution* Proceed as directed in the chapter. To locate the spots, heat the plate at 105° for 5 min, cool, and spray with potassium bismuth iodide TS, then heat again at 105° for 5 min. *Acceptance criteria*: Meets the requirements
MINOCYCLINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS	IMPURITIES/*Organic Impurities*/*Table 6*	*First Supplement to USP39–NF34*	8101	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Footnote c: Change (4*R*,4a*S*,5a*R*,12a*S*)-4-Dimethylamino-3,10,12,12a-tetrahydroxy-7-methylamino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-o

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ctahydrotetracene-2-carboxamide. to: (4*S*,4a*S*,5a*R*,12a*S*)-4-Dimethylamino-3,10,12,12a-tetrahydroxy-7-methylamino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide.
OMEGA-3-ACID ETHYL ESTERS CAPSULES	ASSAY/*Content of EPAee, DHAee, and Total Omega-3-Acid Ethyl Esters*	*Second Supplement to USP39–NF34*	8755	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 21 of *Analysis*: Change C_U = nominal concentration of the total omega-3-acid ethyl esters in the *Sample solution* (g/mL) to: C_U = Capsule fill content of the *Sample solution* (g/mL)
DUTASTERIDE	IM	*USP40–NF35*	3924	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second*	Footnote a:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	PUR ITIES/*Organic Impurities, Procedure 2*/*Table 4*						*Supplement to USP40–NF35*	Change (5?,17 ?)-*N* -[2,5-Bis(trifluor omethyl)phenyl] -3-oxo-4-azaan drost-17 carboxamide. to: (5?,1 7?)-*N* -[2,5-Bis(trifluor omethyl)phenyl] -3-oxo-4-azaan drostane-17-car boxamide.
CARBIDOPA	ASSAY/ *Procedure*	*USP39–NF34*	2924	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 3: Change *Mobile phase*: Alcohol and 0.05 M monobasic sodium phosphate, adjusted with phosphoric acid to a pH of 2.7 (5:95) to: *Buffer*: 0.05 M monobasic sodium

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								phosphate, adjusted with phosphoric acid to a pH of 2.7 *Mobile phase*: Alcohol and *Buffer* (5:95)
DIGOXIN TABLETS	IDENTIFICATION/*A.*	*USP39–NF34*	3494	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the test for *Related glycosides* under *Digoxin*, except to omit the use of the *Gitoxin standard solution*. to: Apply 10 µL of the *Test solution* and 10 µL of the *Standard solution* on a line parallel to and about 2.5

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								cm from the bottom edge of a reversed-phase thin-layer chromatographic plate coated with a 0.25-mm layer of chromatographic silica gel mixture to which is permanently bonded octadecylsilane (C18). Allow the spots to dry, and place the plates in a developing chamber containing a mixture of methanol and water (7:3). Develop the chromatogram until the solvent front has moved about 15 cm above the line of application.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Remove the plate, and allow the solvent to evaporate. Spray the plate with *Chloramine T–trichloroacetic acid reagent*, freshly mixed, and heat in an oven at 110° for 10 minutes.
STERILE PRODUCT PACKAGING?INTEGRITY EVALUATION	5. PRODUCT–PACKAGE QUALITY REQUIREMENTS AND THE MAXIMUM ALLOWABLE LEAKAGE LIMIT/*5.1 Sterility and Product Formulation Content must be Preserved; Gas Headspace Content Preservation is not Required*	*First Supplement to USP39–NF34*	7764	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 3 of paragraph 5: Change ultra-cold storage (<80°) to: ultra-cold storage (??80°)
CIPROFLOXAC	ADDITIONAL R	*Second*	8600	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second*	Line 2 of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
IN HYDROCHLORIDE	EQUIREMENTS/*USP Reference Standards <11>*	*Supplement to USP39–NF35*					*Supplement to USP40–NF35*	Ciprofloxacin Ethylenediamine Analog RS: Change 7-(2-Aminoethylamino)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid. $C_{15}H_{16}FN_3O_3$ 305.30 to: 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[(2-aminoethyl)amino]-3-quinolinecarboxylic acid hydrochloride. $C_{15}H_{16}FN_3O_3 \cdot HCl$ 341.77
ROPINIROLE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 1*	*Second Supplement to USP39–NF34*	8814	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 2 of *Buffer 1*: Adjust with *Solution A* to a pH of 4.0. to: Adjust with *Solution A* to a pH of 4.0. Dilute with water to 1

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								L.
CALCIUM GLUCONATE	CHEMICAL INFORMATION	*USP39–NF34*	2877	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 5: Change [18016-24-5]. to: [66905-23-5].
PHENYTOIN SODIUM	IDENTIFICATION/*B. Identification Tests—General, Sodium <191>*	*USP39–NF34*	5388	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2: Change tetramethylammonium hydroxide solution, to: tetramethylammonium hydroxide TS,
VITAMIN A ORAL LIQUID PREPARATION	ASSAY/*Vitamin A*	*USP39–NF34*	6374	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 7 of *Analysis*: Change Result = $(r_U/r_S) \times (C/W) \times (V/D) \times U \times (100/L)$ to: Result = $(r_U/r_S) \times (C/W) \times D \times U \times (100/L)$ AND Line 16 of the *Analysis*: Delete *V* = volume of the *Sample solution* (mL)
OXYMETAZOLI	ADDITIONAL R	*First*	8116	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First*	USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NE HYDROCHLORIDE	EQUIREMENTS/*USP Reference Standards <11>*	*Supplement to USP39–NF34*					*Supplement to USP40–NF35*	Oxymetazoline Related Compound A RS: Change *N*-(2-Aminoethyl)-2-[4-(*tert*-butyl)-3-hydroxy-2,6-dimethylphenyl]acetamide. $C_{16}H_{26}N_2O_2$ 278.39 to: *N*-(2-Aminoethyl)-2-[4-(*tert*-butyl)-3-hydroxy-2,6-dimethylphenyl]acetamide hydrochloride. $C_{16}H_{26}N_2O_2 \cdot HCl$ 314.85
DESLORATADINE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Second Supplement to USP39–NF34*	8607	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Desloratadine Related Compound B RS: Change 8-Chloro-11-(1,2,3,6-tetrahydropyridin-4-yl)-6,1

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								1-di hydro-5*H* -benzo[5,6]cycl ohe pta[1,2-*b*]pyridine. $C_{19}H_{19}ClN_2$ 310.82 to: 8-Chloro-11-(1, 2,3,6-tetrahydro pyridin-4-yl)-6,1 1-di hydro-5*H* -benzo[5,6]cycl ohe pta[1,2-*b*]pyridine hydrochloride. $C_{19}H_{20}Cl_2N_2$ 347.28
NORFLOXACIN	SPECIFIC TESTS/*Loss on Drying <731>*	*USP39–NF34*	5101	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *Analysis*: Change Dry at 100° to constant weight. to: Dry under vacuum at a pressure not exceeding 5

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mm of mercury at 100° to constant weight.
PROPOFOL INJECTABLE EMULSION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	5575	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Propofol Related Compound B RS: Change 2,6-Diisopropylbenzoquinone. to: 2,6-Diisopropyl-1,4-benzoquinone.
HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS	*Appendix 3: Types of Biological Safety Cabinets*/Class II	*First Supplement to USP39–NF34*	7721	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 5 of *Type A1 (formerly, Type A)*: Change radionucleotides to: radionuclides AND Line 5 of *Type A2 (formerly, Type B3)*: Change radionucleotides to: radionuclides

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Line 5 of *Type B1*: Change radionucleotides to: radionuclides AND Line 5 of *Type B2 (total exhaust)*: Change radionucleotides to: radionuclides
PERINDOPRIL ERBUMINE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP39–NF34*	8127	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Perindopril Related Compound A RS: Change (2*S*,3a*S*,7a*S*)-Octahydro-1*H*-indole-2-carboxylic acid hydrochloride. $C_{17}H_{28}N_2O_5 \cdot HCl$ 205.68

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: (2*S*,3a*S*,7a*S*)-Octahydro-1*H*-indole-2-carboxylic acid. $C_9H_{15}NO_2$ 169.22
CALCIUM GLUCONATE INJECTION	DEFINITION	*USP39–NF34*	2879	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 8: Change It may contain sodium hydroxide added for adjustment of the pH. to: It may contain sodium hydroxide or hydrochloric acid added for adjustment of the pH.
POTASSIUM CITRATE EXTENDED-RELEASE TABLETS	OTHER COMPONENTS/*Content of Potassium*	*USP39–NF34*	5465	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 10 of *Analysis*: Change Result = $(C/C_U) \times [M_r/(3 \times A_r)] \times 100$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: Result = $C \times 100/C_U$ AND Line 13 of *Analysis*: Change C_U = nominal concentration, based on the *Assay* value, of potassium citrate monohydrate in the *Sample solution* (µg/mL) M_r = molecular weight of potassium citrate monohydrate, 324.41 A_r = atomic weight of potassium, 39.10 to: C_U = concentration of potassium citrate

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								anhydrous ($C_6H_5K_3O_7$) in the *Sample solution* calculated from the *Assay* value of potassium citrate monohydrate ($C_6H_5K_3O_7 \cdot H_2O$) (µg/mL)
ST. JOHN'S WORT	SPECIFIC TESTS	*USP39–NF34*	6817	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Insert missing test: *Articles of Botanical Origin <561>, Methods of Analysis, Total Ash:* NMT 5.0%
OXYMETAZOLINE HYDROCHLORIDE	IMPURITIES/*Organic Impurities*/*Table 2*	*First Supplement to USP39–NF34*	8116	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Row 2 of Column 1: Change Oxymetazoline related compound A to: Oxymetazoline related compound A[a] AND Add footnote a:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								N-(2-Aminoethyl)-2-[4-(*tert*-butyl)-3-hydroxy-2,6-dimethylphenyl]acetamide.
ANALYTICAL DATA—INTERPRETATION AND TREATMENT	APPENDIX C: EXAMPLES OF OUTLIER TESTS FOR ANALYTICAL DATA/*Hampel's Rule*	*USP39–NF34*	767	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Row 13 of Column 4 of *Table 5. Test Results of Re-Applied Hampel's Rule*: Change 0.14 to: 0.15
PARICALCITOL INJECTION	IMPURITIES/*Organic Impurities/ Chromatographic system/ Columns*	*USP39–NF34*	5279	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *Guard*: Change 4.6-mm × 7.5-mm; packing L1 to: 4.6-mm × 7.5-mm or 4.6-mm × 10-mm; packing L1
TRAVOPROST OPHTHALMIC SOLUTION	ADDITIONAL REQUIREMENTS/*USP*	*USP39–NF34*	6226	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Travoprost Related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Reference Standards <11>							Compound A RS: Change (5*Z*,13*E*)-(9*S*,11*R*,15*R*)-9,11,15-Trihydroxy-16-(*m*-trifluoromethylphenoxy)-17,18,19,20-tetranor-5,13-prostadienoic acid. to: (5*Z*,13*E*)-(9*S*,11*R*,15*R*)-9,11,15-Trihydroxy-16-(*m*-trifluoromethylphenoxy)-17,18,19,20-tetranor-5,13-prostadienoic acid or (*Z*)-7-((1*R*,2*R*,3*R*,5*S*)-3,5-Dihydroxy-2-{(*R*,*E*)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								enyl}cyclopentyl)hept-5-enoic acid.
DANTROLENE SODIUM	IDENTIFICATION/*D.*	*First Supplement to USP39–NF34*	8035	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of *Solution A*: Change tetramethylammonium hydroxide solution to: tetramethylammonium hydroxide TS
PERINDOPRIL ERBUMINE	IMPURITIES/*Organic Impurities*/*Table 2*	*First Supplement to USP39–NF34*	8127	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of footnote g: Change ocatahydro to: octahydro
FLUORESCEIN SODIUM	ASSAY/*Procedure*	*USP39–NF34*	3960	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 3 of *Standard stock solution*: Change 1.0 mg/mL of fluorescein sodium in *Diluent* is prepared as follows. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								1.0 mg/mL of fluorescein sodium is prepared as follows.

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 12
- Page 13
- Page 14
- Page 15
- Page 16
- Page 17
- Page 18
- Page 19
- Page 20
- …
- Next page Next ›
- Last page Last »